CGEM
CGEM
NASDAQ · Biotechnology

Cullinan Therapeutics Inc

$14.55
-0.17 (-1.15%)
As of May 9, 9:40 PM ET ·
Analyst Consensus
Strong Buy
19
Analysts
High
Coverage
Buy 18 95%
Hold 1 5%
Sell 0 0%
Price Target
Analyst Price Target +47.4% upside
Low Target $16.94
Average Target $21.45
High Target $32.37
Current Price $14.55
Current
$14.55
Target
$21.45
$16.94 $21.45 avg $32.37
Scenario Analysis
Bear Case
$16.94
16.4%
Low target
Base Case
$21.45
+47.4%
Avg target
Bull Case
$32.37
+122.5%
High target
Risk/Reward
7.5x
Highly favorable
Price in Context
52-Week High
$16.74
-13.1% from high
52-Week Low
$5.68
+156.2% from low
Target vs 52W High
$21.45
+28.1% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 40 75% $257.58 +27.8%
AMGN
Amgen Inc
Hold 44 48% $190.87 -42.5%
GILD
Gilead Sciences Inc
Strong Buy 39 79% $362.68 +176.2%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 +2.0%
REGN
Regeneron Pharmaceuticals
Strong Buy 38 79% $76.80 -89.3%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 75% $102.31 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 27 96% $114.11 -19.5%
INSM
Insmed Inc
Strong Buy 28 96% $143.40 +41.5%